Neuromuscular Junction Disorders


Disorders affecting the neuromuscular junction (NMJ) are among the most interesting and rewarding seen in the electromyography (EMG) laboratory. These disorders are generally pure motor syndromes that usually preferentially affect proximal, bulbar, or extraocular muscles. They are confused occasionally with myopathies. With knowledge of normal NMJ physiology (see Chapter 6 ), most of the abnormalities affecting the NMJ can be differentiated using a combination of nerve conduction studies, repetitive stimulation, exercise testing, and needle EMG.

NMJ disorders can be classified into immune-mediated, toxic or metabolic, and congenital syndromes ( Box 37.1 ). They usually are distinguished by their clinical and electrophysiologic findings ( Tables 37.1 and 37.2 ). All are uncommon, but among them, myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the disorders most often encountered in the EMG laboratory. Both are immune-mediated disorders. In MG, the autoimmune attack is postsynaptic; in LEMS, the presynaptic membrane is the target of attack. Every electromyographer must understand the electrophysiology of these disorders so that appropriate electrodiagnostic tests can be applied and the correct diagnosis not overlooked.

Box 37.1
Disorders of the Neuromuscular Junction
Adapted in part from Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol . 2015;14(4):420–434.

Immune-Mediated Disorders

  • Myasthenia gravis

  • Lambert-Eaton myasthenic syndrome

Toxic/Metabolic Disorders

  • Botulism

  • Snake venom poisoning

  • Arthropod venom poisoning (e.g., from a black widow spider)

  • Organophosphates, insecticide poisoning (e.g., as from malathion, parathion)

  • Hypermagnesemia

Congenital Myasthenic Syndromes

  • Presynaptic

    • Choline acetyltransferase deficiency (ChAT) a

      a Of the congenital myasthenic syndromes, these by far are the most common.

    • Paucity of synaptic vesicles and reduced quantal release

    • SNAP25B deficiency

    • Synaptotagmin 2 deficiency

  • Synaptic basal lamina-associated

    • Endplate acetylcholinesterase deficiency a

    • Laminin-β2 deficiency

  • Defects in acetylcholine receptor

    • Primary acetylcholine receptor deficiency a

    • Kinetic defects in the acetylcholine receptor a

    • Slow-channel syndrome a

    • Fast-channel syndrome

  • Defects in endplate development and maintenance

    • Agrin deficiency

    • LRP4 myasthenia

    • MuSK deficiency

    • Dok-7 myasthenia a

    • Rapsyn deficiency a

  • Congenital defect of glycosylation

    • GFPT1 myasthenia

    • DPAGT1 myasthenia

    • ALG2 and ALG14

  • Other myasthenic syndromes

    • PREPL deletion syndrome

    • Na-channel myasthenia

    • Plectin deficiency

  • Myasthenic syndrome associated with centronuclear myopathies

Table 37.1
Clinical Characteristics of Neuromuscular Junction Disorders.
Disorder Temporal Onset Ocular Sx Bulbar Sx Reflexes Autonomic Sx Sensory Sx GI Sx
Myasthenia gravis Subacute + + Normal a
Lambert-Eaton myasthenic syndrome Subacute +/− +/− Reduced +/− +/−
Botulism Acute + + Normal a + +
Congenital myasthenia Congenital or pediatric + +/− Normal a
+, Commonly present; +/−, may be seen occasionally; −, usually not present; GI , gastrointestinal; Sx , symptoms/signs.

a May be reduced in proportion to the degree of muscle weakness.

Table 37.2
Electrophysiologic Characteristics of Neuromuscular Junction Disorders.
Disorder Compound Muscle Action Potential Amplitude at Rest Decrement: 3 Hz Increment: 50 Hz SF-EMG Repetitive Compound Muscle Action Potential Electromyography: Fibrillation Potentials/Positive Waves Electromyography: Motor Unit Action Potential
Myasthenia gravis Normal + Increased jitter/blocking Normal/SSP
Lambert-Eaton myasthenic syndrome Decreased + + Increased jitter/blocking Normal/SSP
Botulism Decreased + + (unless severe blocking) Increased jitter/blocking + Normal/SSP
Congenital myasthenia Normal +∗ Increased jitter/blocking +∗ Normal/SSP
+, Commonly seen; −, usually not present; +∗, may be present in some of the syndromes (usually congenital acetylcholinesterase [AChE] deficiency or slow-channel congenital myasthenic syndrome); SF-EMG , single-fiber electromyography; SSP , small, short, polyphasic.

Myasthenia Gravis

MG, the best understood of all the autoimmune diseases, is caused by an immunoglobulin G (IgG)–directed attack on the NMJ, aimed specifically at the nicotinic acetylcholine receptor (ACHR) in the vast majority of cases. The role of these anti-ACHR antibodies as the cause of MG has been proved through a variety of experimental steps: (1) antibodies are present in the serum of most patients with MG; (2) antibodies passively transferred to animals produce experimental myasthenia; (3) removal of antibodies allows recovery; and (4) immunization of animals with ACHRs produces antibodies and can provoke an autoimmune disease that closely resembles the naturally occurring disease.

The mechanism of antibody damage to the ACHR and postsynaptic membrane involves several steps. First, binding of the antibody to the receptor can directly block the binding of acetylcholine (ACH). Second, there is a complement-directed attack, with destruction of the ACHR and postjunctional folds. Last, antibody binding can result in an increase in the normal removal of ACHRs from the postsynaptic membrane (modulation). Thus, although the amount of ACH released is normal, there is reduced binding of ACH to the ACHR, resulting in a smaller endplate potential and a reduced safety factor of NMJ transmission.

A subset of patients with MG clinically (approximately 8%–15%) will not demonstrate antibodies to ACHR (so-called “seronegative” cases). In this subset, however, approximately 40%–50% will have an antibody to muscle-specific tyrosine kinase (MuSK). MuSK is a surface receptor involved in the clustering of ACHRs during development. Other rare seronegative patients have antibodies to the low-density lipoprotein receptor–related protein 4 (LRP4). LRP4 binds with agrin (another NMJ protein) to form a complex that assists with activation of MuSK. Patients without antibodies to ACHR, MuSK, and LRP4 are referred to as “triple seronegative.”

Clinical

Patients with MG present with muscle fatigue and weakness. Because the disorder is limited to the NMJ, there is no abnormality of mental state or sensory or autonomic function. In patients with antibodies to ACHR, myasthenic weakness characteristically affects the extraocular, bulbar, or proximal limb muscles. Eye findings are the most common, with ptosis and extraocular muscle weakness occurring in more than 50% of patients at the time of presentation and developing in more than 90% of patients sometime during their illness. Extraocular weakness frequently begins asymmetrically, with one eye involved and the other spared. A very small degree of extraocular weakness is experienced by the patient as visual blurring or double vision. Myasthenic weakness has been known to mimic third, fourth, and sixth nerve palsies and, rarely, an intranuclear ophthalmoplegia. Unlike true third nerve palsies, however, MG never affects pupillary function. Fixed extraocular muscle weakness may occur late in the illness, especially if untreated.

Bulbar muscle weakness is next most common after extraocular weakness. This may result in difficulty swallowing, chewing, and speaking. Patients may develop fatigability and weakness of mastication, with the inability to keep the jaw closed after chewing. Myasthenic speech is nasal (from weakness of the soft palate) and slurred (from weakness of the tongue, lips, and face) but without any difficulty with fluency. Weakness of the soft palate may also result in nasal regurgitation (i.e., liquid coming out the nose when drinking). When myasthenic patients develop limb weakness, it usually is symmetric and proximal. Patients note difficulty getting up from chairs, going up and down stairs, reaching with their arms, or holding up their head. Rare patients present with an isolated limb-girdle form of MG and never develop eye movement or bulbar muscle weakness. It is these patients who are most often misdiagnosed with myopathy.

In contrast to the clinical syndrome seen in MG with anti-ACHR antibodies, the clinical characteristics of patients with anti-MuSK antibody–associated MG include female predominance, prominent bulbar, neck, shoulder and respiratory involvement, and a severe presentation that occurs at a younger age than MG associated with anti-ACHR antibodies. Three clinical patterns are present in anti-MuSK antibody–associated MG: (1) severe oculobulbar weakness along with tongue and facial atrophy, and tongue fasciculations; (2) marked neck, shoulder, and respiratory weakness with little or no ocular weakness; and (3) a pattern similar to anti-ACHR antibody–associated MG. In addition, patients with anti-MuSK antibody–associated MG are often unresponsive or intolerant to cholinesterase inhibitors, and some actually worsen.

The distinguishing clinical feature of MG, whether seropositive (ACHR, MuSK, LRP4) or seronegative, is pathologic fatigability (i.e., muscle weakness that develops with continued use). Patients improve after rest or upon rising in the morning and worsen as the day proceeds. Although generalized fatigue is common in many neurologic and non-neurologic disorders, NMJ fatigue is limited to muscular fatigue alone, which progresses to frank muscle weakness with use. Patients with MG do not generally experience a sense of mental fatigue, tiredness, or sleepiness.

The clinical examination in a patient suspected of having MG is directed at examining muscular strength and demonstrating pathologic fatigability. To demonstrate subtle weakness, it is helpful to observe the patient performing functional tasks, such as rising from a chair or from the floor or walking, rather than relying on manual muscle strength testing alone. Pathologic fatigability may be demonstrated by having the patient look up for several minutes (to determine if ptosis or extraocular weakness is present), count aloud to 100 (to determine if nasal or slurred speech is present), or by repetitively testing the neck or the proximal limb muscles (for example, with both shoulders abducted, the examiner repetitively pushes down on both arms several times, looking for fatigable weakness). In patients with ptosis, the ice bag test can be very helpful. Ice is applied over the forehead for several minutes to cool the underlying muscles. In MG, ptosis may improve markedly with cooling. The remainder of the neurologic examination should be normal. Deep tendon reflexes are generally preserved or, if reduced, are reduced in proportion to the degree of muscle weakness.

Most patients with MG have generalized disease. However, as many as 15% of patients have the restricted ocular form of the disease. In these patients, myasthenic symptoms remain restricted to the extraocular and eyelid muscles. When a patient first presents with fluctuating extraocular weakness, it is impossible to predict from either clinical or laboratory testing which patients subsequently will generalize and which will remain with relatively benign restricted ocular symptoms. If a patient’s symptoms remain restricted to the ocular muscles for 1–2 years, however, there is a high probability that the myasthenia will never generalize and will remain restricted to the extraocular and eyelid muscles.

More recently, MG has been seen as a rare complication in cancer patients treated with immune checkpoint inhibitors (ICPIs). These are monoclonal antibodies that target cytoplasmic T-lymphocyte associated antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1), or programmed cell death ligand-1 (PD-L1). These agents inhibit normal physiologic mechanisms that protect against autoimmunity. Although they are highly effective as immunotherapy in several types of refractory cancers, they can result in a large number of immune-related adverse effects (irAEs), including several neuromuscular conditions. Among these are MG, myositis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy. In patients who develop MG, the ACHR antibodies are typically positive (although some are negative) and the electrophysiology is similar to that seen in sporadic autoimmune MG. In our experience, MG provoked by ICPIs is often associated with myositis, is very severe, and can be very difficult to treat. Plasma exchange and high-dose steroids are usually required, in addition to immediate cessation of the involved drug.

Autoimmune MG may be seen in two other groups of patients aside from those with idiopathic autoimmune myasthenia. First, transient neonatal MG may occur in babies born to mothers with MG. This occurs when maternal autoantibodies pass through the placenta, resulting in the same clinical syndrome in newborn infants. The illness usually is mild and self-limited and disappears after the first few months of life as the maternal antibodies are degraded. MG may also be seen in patients treated with penicillamine. The clinical syndrome is similar to idiopathic MG, including the presence of anti-ACHR antibodies, except that most patients slowly improve once the penicillamine has been discontinued.

Electrophysiologic Evaluation

Like other disorders affecting the NMJ, the electrophysiologic evaluation of MG involves routine nerve conduction studies, repetitive nerve stimulation (RNS), exercise testing, routine EMG, and, in some cases, single-fiber EMG (SF-EMG) ( Box 37.2 ).

Box 37.2
Electrophysiologic Evaluation of Myasthenia Gravis
CMAP , Compound muscle action potential; NMJ , neuromuscular junction.

  • 1.

    Routine motor and sensory nerve conduction studies. Perform routine motor and sensory nerve conduction studies, preferably a motor and sensory nerve in one upper and one lower extremity. CMAP amplitudes should be normal. If CMAP amplitudes are low or borderline, repeat distal stimulation immediately after 10 seconds of exercise to exclude a presynaptic NMJ transmission disorder (e.g., Lambert-Eaton myasthenic syndrome).

  • 2.

    Repetitive nerve stimulation (RNS) and exercise testing. Perform slow RNS (3 Hz) on at least one proximal and one distal motor nerve. Always try to study weak muscles. If any significant decrement (>10%) is present, repeat to ensure that the decrement is reproducible. If there is no significant decrement at baseline, exercise the muscle for 1 minute, and repeat RNS at 1, 2, 3, and 4 minutes looking for a decrement, secondary to post-exercise exhaustion. If at any time a significant decrement is present (at baseline or following postexercise exhaustion), exercise the muscle for 10 seconds and immediately repeat RNS, looking for postexercise facilitation (repair of the decrement).

  • 3.

    Needle electromyography (EMG). Perform routine needle EMG of distal and proximal muscles, especially weak muscles. Patients with moderate to severe myasthenia gravis may display unstable or short, small, polyphasic motor unit action potentials. Recruitment is normal or early. Needle EMG must exclude severe denervating disorders or myotonic disorders, which may display an abnormal decrement on RNS.

  • 4.

    Single-fiber EMG (SF-EMG). If the previous items are normal or equivocal in a patient strongly suspected of having myasthenia gravis, perform SF-EMG in the extensor digitorum communis and, if necessary, one other muscle, looking for jitter and blocking. It is always best to study a weak muscle. Normal SF-EMG in a clinically weak muscle excludes an NMJ disorder.

Nerve Conduction Studies

In any patient suspected of having MG, routine motor and sensory nerve conduction studies cannot be omitted. At least one motor and sensory conduction study should be performed in an upper and lower extremity, but the number of nerves studied often depends on the clinical context. Particular attention must be paid to compound muscle action potential (CMAP) amplitudes. Normal CMAP amplitudes are an important and expected finding in MG, in direct contrast to LEMS, wherein baseline CMAPs usually are diffusely low. In only a small number of patients with MG (3%–15%), the baseline CMAPs at rest are below the normal range.

Routine nerve conduction studies also must be performed to ensure the integrity of any nerve that subsequently will be used for RNS. A decrement on RNS can be seen in various denervating conditions (e.g., neuropathies, motor neuron disorders, inflammatory myopathies) and myotonic disorders, in addition to primary disorders of the NMJ. For instance, a decrement on RNS of the ulnar nerve may be seen in a severe ulnar neuropathy with denervation; such a finding in this context does not imply a primary NMJ disorder.

Repetitive Nerve Stimulation

After the routine nerve conduction studies are completed, RNS studies are performed (see Chapter 6 ). These studies are abnormal in more than 50%–70% of patients with generalized MG but often are normal in patients with the restricted ocular form of MG. A decremental response on RNS is the electrical correlate of clinical muscle fatigue and weakness. In normal subjects, slow RNS (3 Hz) results in little or no decrement of the CMAP, whereas in MG, a CMAP decrement of 10% or more is characteristically seen ( Fig. 37.1A ). Both distal and proximal nerves should be tested. Although distal nerves are technically easier to study, the diagnostic yield increases with stimulation of proximal nerves (e.g., spinal accessory or facial nerves). This is not unexpected, because the proximal muscles usually are much more involved clinically than the distal ones. Facial RNS is especially important to perform in suspected anti-MuSK antibody–associated MG, wherein the yield of finding an abnormal decrement is much higher when examining a facial muscle than a limb muscle. This likely reflects the severe facial and bulbar involvement in some patients with anti-MuSK antibody–associated MG.

Fig. 37.1, Repetitive nerve stimulation (3 Hz) in myasthenia gravis.

Exercise Testing

Exercise testing should be routinely used with all RNS studies (see Chapter 6 ). If there is no significant decrement on RNS studies at baseline (<10% decrement), the patient should perform 1 minute of exercise, followed by RNS at 1-minute intervals for the next 3–4 minutes, looking for a CMAP decrement secondary to postexercise exhaustion. If at any time, either at baseline or following exercise, a significant decrement develops, the patient should perform a brief 10-second maximum isometric contraction, immediately followed by slow RNS, looking for an increment in the CMAP and “repair” of the decrement secondary to postexercise facilitation ( Fig. 37.1 ).

Electromyography

Every patient evaluated for a possible NMJ disorder should have routine needle EMG performed, paying particular attention to weak muscles. EMG examination is done for two reasons. First, and most important, severe denervating disorders (e.g., motor neuron disease, polyneuropathy, inflammatory myopathy) and myotonic disorders need to be excluded because they also can show a decremental CMAP response on RNS. Second, the needle examination may demonstrate motor unit action potential (MUAP) abnormalities suggestive of an NMJ disorder: unstable MUAPs; small, short-duration MUAPs similar to myopathic MUAPs; or both.

Unstable MUAPs (see Chapter 15 ) occur when individual muscle fibers are either blocked or come to action potential at varying intervals, which leads to MUAPs that change in configuration from impulse to impulse. If some muscle fibers of a motor unit are blocked and never come to action potential, the motor unit effectively loses muscle fibers, becoming short, small, and polyphasic, similar to MUAPs seen in myopathy. Otherwise, the needle EMG findings in NMJ disorders usually are normal. In general, fibrillation potentials and other abnormal spontaneous activity are not seen in NMJ disorders, with the important exception of botulism (see section on Botulism).

Single-Fiber Electromyography

When a motor axon is depolarized, the action potential normally travels distally and excites all the muscle fibers within that motor unit at more or less the same time ( Fig. 37.2 ). This variation in the time interval between the firing of adjacent single muscle fibers from the same motor unit is termed jitter and primarily reflects variation in NMJ transmission time. If the NMJ is compromised, the time it takes for the endplate potential to reach threshold is prolonged, which results in greater-than-normal variation between firing of adjacent muscle fibers. If the prolongation is severe enough, the muscle fiber may never reach action potential, resulting in blocking of the muscle fiber.

Fig. 37.2, Single-fiber electromyography (SF-EMG).

SF-EMG is used to measure the relative firing of adjacent single muscle fibers from the same motor unit and can detect both prolonged jitter as well as blocking of muscle fibers. It is important to note that, whereas the clinical correlate of blocking is muscle weakness, there is no clinical correlate to increased jitter. Thus the main advantage of SF-EMG over RNS is that the single-fiber study may be abnormal, showing increased jitter, even in patients without overt clinical weakness. In contrast, for RNS studies to be abnormal, the NMJ disorder must be sufficiently severe that blocking (the electrophysiologic correlate of weakness) also occurs, leading to a decremental response.

SF-EMG is best reserved for those electromyographers who are well trained in its use and who perform SF-EMG on a routine basis. It is a technically demanding procedure for both the patient and the electromyographer. In contrast to routine EMG, usually only one or two muscles are studied. Often, the extensor digitorum communis muscle in the forearm is selected for study. For most patients, this muscle can be steadily activated for a prolonged period and is relatively free of age-related changes. In addition, studying a clinically involved muscle is always useful. A normal single-fiber examination of a clinically weak muscle effectively rules out the diagnosis of MG.

The goal of SF-EMG is to study two adjacent single muscle fibers, known as a pair, from the same motor unit. This is accomplished by first changing the filters on the EMG machine. The low-frequency filter (high-pass) is increased to either 500 or 1000 Hz (normally 10 Hz in routine EMG). By using a high-pass filter of 500 or 1000 Hz, the amplitudes of distant muscle fiber potentials are attenuated while those of the nearby fibers are preserved. The dedicated SF-EMG needle is a specially constructed needle with the active electrode (G1) located in a port along the posterior shaft of the needle and with a smaller leading surface area than the conventional concentric needle electrode ( Fig. 37.3 ). The reference electrode (G2) is the needle shaft. The result of these two modifications is that single-fiber muscle action potentials are recorded only if they are within 200–300 μm of the needle. The needle is placed in the muscle, and the patient is asked to activate the muscle in an even and constant fashion. The needle is moved until a single muscle fiber potential is located. With this single muscle fiber potential triggered on a delay line, the needle is slightly and carefully moved or rotated to look for a second potential that is time locked to the first potential (signifying that it is from the same motor unit).

Fig. 37.3, Single-fiber electromyography needle.

SF-EMG is technically demanding. The optimal single-fiber potentials are those in which the amplitude is at least 200 μV in amplitude and the rise time is less than 300 μs. If a time-locked second potential is located, an interpotential interval between the two potentials (i.e., the pair) can be measured. By recording multiple consecutive firings of the muscle fiber action potential pairs, the difference between consecutive interpotential intervals can be calculated. This variation between consecutive interpotential intervals is the jitter. By recording 50–100 subsequent potentials, the mean consecutive difference (MCD), a measure of jitter, can be calculated between the triggered potential and the time-locked second single muscle fiber potential. Most modern EMG machines have programs that automatically perform the MCD calculation. This procedure is then repeated until 20 separate single-fiber pairs are collected, to calculate a mean MCD. This value is compared with the normal mean MCD for the muscle studied and the patient’s age ( Table 37.3 ). There is also an upper limit of normal jitter for an individual pair, based on the muscle studied and the patient’s age. For the upper limit of jitter of a muscle to be deemed abnormal, more than 10% of the pairs must exceed the upper limit of normal (e.g., for 20 pairs, at least two must be abnormal). To make a diagnosis of an NMJ disorder, either the mean jitter must be abnormal or the upper limit of normal jitter must be abnormal in more than 10% of individual pairs. However, in most NMJ disorders, both measures will be abnormal. Increased jitter is consistent with an NMJ disorder ( Fig. 37.4 ). In addition to increased jitter, blocking may be seen on SF-EMG. Two time-locked, single-fiber muscle potentials from the same motor unit normally fire together. If the triggered potential fires steadily while the second potential fires only intermittently, blocking is occurring. Blocking, which is another marker of NMJ disease, usually occurs only when the jitter is markedly prolonged (e.g., MCD > 80–100 μs).

Table 37.3
Reference Values for Jitter Measurements During Voluntary Muscle Activation.
From Bromberg MB, Scott DM, Ad Hoc Committee of the AAEM Single Fiber Special Interest Group. Single fiber EMG reference values: reformatted in tabular form. Muscle Nerve . 1994;17:820–821. With permission.
Muscle 10 Years 20 Years 30 Years 40 Years 50 Years 60 Years 70 Years 80 Years 90 Years
Frontalis 33.6/49.7 33.9/50.1 34.4/51.3 35.5/53.5 37.3/57.5 40.0/63.9 43.8/74.1
Orbicularis oculi 39.8/54.6 39.8/54.7 40.0/54.7 40.4/54.8 40.9/55.0 41.8/55.3 43.0/55.8
Orbicularis oris 34.7/52.5 34.7/52.7 34.9/53.2 35.3/54.1 36.0/55.7 37.0/58.2 38.3/61.8 40.2/67.0 42.5/74.2
Tongue 32.8/48.6 33.0/49.0 33.6/50.2 34.8/52.5 36.8/56.3 39.8/62.0 44.0/70.0
Sternocleidomastoid 29.1/45.4 29.3/45.8 29.8/46.8 30.8/48.8 32.5/52.4 34.9/58.2 38.4/62.3
Deltoid 32.9/44.4 32.9/44.5 32.9/44.5 32.9/44.6 33.0/44.8 33.0/45.1 33.1/45.6 33.2/46.1 33.3/46.9
Biceps 29.5/45.2 29.6/45.2 29.6/45.4 29.8/45.7 30.1/46.2 30.5/46.9 31.0/48.0
Extensor digitorum communis 34.9/50.0 34.9/50.1 35.1/50.5 35.4/51.3 35.9/52.5 36.6/54.4 37.7/57.2 39.1/61.1 40.9/66.5
Abductor digiti minimi 44.4/63.5 44.7/64.0 45.2/65.5 46.4/68.6 48.2/73.9 51.0/82.7 54.8/96.6
Quadriceps 35.9/47.9 36.0/48.0 36.5/48.2 37.5/48.5 39.0/49.1 41.3/50.0 44.6/51.2
Tibialis anterior 49.4/80.0 49.3/79.8 49.2/79.3 48.9/78.3 48.5/76.8 47.9/74.5 47.0/71.4 45.8/67.5 44.3/62.9
95% confidence limits for upper limit of mean jitter/95% confidence limits for jitter values of individual fiber pairs (μs). This table was derived from data obtained with conventional voluntary activation and a standard dedicated SF-EMG needle electrode.

Fig. 37.4, Single-fiber electromyography recordings.

The classic SF-EMG procedure is based on voluntary activation. The patient is instructed to maintain a low level of constant contraction as the electromyographer slowly moves the SF-EMG needle to a location where one spike is seen and triggered. Other spikes which are time locked to the index potential are then looked for, often by slightly rotating the needle. However, in normal muscle, it is uncommon for two muscle fibers from the same motor unit to be located adjacent to each other (recall the “mosaic pattern” of motor unit innervation of muscle). Thus finding a “pair” on SF-EMG is often difficult and time consuming. An alternative method was devised using stimulated single fiber . Using this method, recording with the SF-EMG needle is identical. However, voluntary activation is not used. The nerve to the muscle being recorded is stimulated, either with a needle or surface electrode, usually at 10 Hz. This greatly simplifies recording single-fiber potentials. However, this method has created several technical challenges. One cannot supramaximally stimulate a nerve as this would cause too much artifact from the contracting muscle, as well as being too painful for the patient. Thus submaximal stimulation is used. However, this often results in some fibers being consistently stimulated whereas others (potentially slightly farther away or deeper) are on the edge of depolarization. If not recognized, recording these potentials can lead to the mistaken appearance of increased jitter and block. In addition, the jitter using stimulated SF-EMG only represents the variation in firing of one NMJ. In conventional voluntary SF-EMG, one is triggering off of one single fiber, with its own jitter, and recording another single fiber of the same motor unit, with its separate jitter. Thus normal jitter values in voluntary SF-EMG are larger than stimulated SF-EMG values as they represent two as opposed to one NMJ. Although stimulated SF-EMG can be performed much more quickly than voluntary SF-EMG, it is a much more advanced skill with many more technical challenges to obtaining valid data.

More recently, the regular disposable concentric EMG needle has become the preferred needle for SF-EMG studies. The dedicated SF-EMG needle is expensive and needs to be surgically sanitized between patients. Thus the cost of the standard SF-EMG needle, the theoretical risk of transmitting infection (including prion diseases), and patient reluctance to have any procedure performed with a “reused” needle (despite surgical sanitization) prompted this change. Despite the recording area from the smallest concentric needle being much larger than that of the dedicated SF-EMG needle, concentric needles have been found to be acceptable for SF-EMG studies. In one large multicenter study of normal subjects, the jitter of three muscles (orbicularis oculi, frontalis, and extensor digitorum communis) was determined both for voluntary and stimulated studies ( Table 37.4 ). In general, the values for jitter are slightly smaller using a concentric EMG needle compared with a traditional SF-EMG needle.

Table 37.4
Summary of Normal Jitter Values With a Concentric Needle.
From Stålberg E, Sanders DB, Ali S, et al. Reference values for jitter recorded with concentric needle electrodes in healthy controls: a multicenter study. Muscle Nerve . 2016;53(3):351–362.
Muscle
Orbicularis Oculi Frontalis Extensor Digitorum
Voluntary SF-EMG
Mean jitter (μs) 22.9 20.6 23.4
Mean jitter upper limit of normal (μs) 31 28 30
Upper limit of normal for any one pair (μs) 45 38 43
Stimulated SF-EMG
Mean jitter (μs) 19.1 14.5 18.2
Mean jitter upper limit of normal (μs) 27 21 24
Upper limit of normal for any one fiber (μs) 36 28 35

SF-EMG is the most sensitive test to demonstrate impaired NMJ transmission (abnormal in 95%–99% of patients with generalized MG). However, it must be emphasized that although SF-EMG is very sensitive, it is not specific . SF-EMG can be abnormal in both neuropathic and myopathic diseases. Although it might be tempting to perform SF-EMG on any patient with fatigue, this test is best reserved for patients in whom the diagnosis of MG or another NMJ disorder is strongly suspected and in whom all other diagnostic test results, including RNS, have been negative or equivocal. In some patients with the restricted ocular form of MG, all study results, including SF-EMG, may be normal.

Lambert-Eaton Myasthenic Syndrome

LEMS is a disorder of NMJ transmission characterized by reduced release of ACH from the presynaptic terminal. There is now clear evidence that this disorder, like MG, is an immune-mediated disorder. The pathogenesis of LEMS is fairly well understood and in most cases involves the production of IgG antibodies directed at the presynaptic P/Q- and N-type voltage-gated calcium channel (VGCC). These antibodies interfere with the calcium-dependent release of ACH quanta from the presynaptic membrane and subsequently cause a reduced endplate potential on the postsynaptic membrane, resulting in NMJ transmission failure. This has been shown by passively transferring IgG from LEMS patients to animals, where it produces the same physiologic and morphologic changes seen in humans.

Clinical

LEMS is quite rare. Clinically, these patients present with proximal muscle weakness (especially the lower extremities) and fatigability. In addition, deep tendon reflexes are characteristically reduced or absent, which is unusual in MG or myopathy. Autonomic complaints (especially dry mouth) and transient sensory paresthesias may be present. The mechanism of autonomic dysfunction is thought to be due to cross-reaction of the antibody against N-type VGCCs in autonomic ganglia, which have about 60% homology with the P/Q-type VGCC. Bulbar symptoms (ptosis, dysarthria, dysphagia) usually, but not always, are mild, which helps to distinguish this illness from botulism and MG. The distinctive clinical finding is that of muscle facilitation. After a brief period (10 seconds) of intense exercise of a muscle, the power and the deep tendon reflex to that muscle are transiently increased. Rare patients have been diagnosed with LEMS after having been prescribed calcium channel blockers or after having failed to wean from the respirator after anesthesia.

It affects adults, generally those older than 20 years and usually older than 40 years, of whom 70% are male and 30% are female. Patients older than 40 years, usually males and smokers, are at greatest risk. Small cell lung cancer (SCLC) is eventually found in 60% of patients with LEMS. SCLCs express VGCCs, which then initiate and maintain the autoimmune process. Rarely, other tumors are associated with LEMS. The remaining patients, usually younger women, have a primary autoimmune disease without any evidence of carcinoma. Some of these patients also have antibodies to VGCCs. Commercial testing for antibodies to VGCCs is available, although the sensitivity of the test varies depending on the specific antibodies tested and whether the patient has an underlying carcinoma or primary autoimmune disease. Serum IgG antibodies against P/Q-type VGCCs are found in approximately 85% of patients with LEMS, both with and without SCLC. However, these antibodies are not completely specific to LEMS and are rarely associated with other neurological conditions and autoimmune disorders. Antibodies against the N-type VGCCs are found in approximately 30% of patients with LEMS.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here